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Nagi Reddy Dumpa1, Arun Butreddy1, Suresh Bandari1, Michael A. Repka1,2
1Department

of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi
University, MS-38677, USA
2Pii Center for Pharmaceutical Technology, The University of Mississippi, University, MS-38677, USA
Email: ndumpa@go.olemiss.edu

RESULTS

PURPOSE
The main objective of this study was to develop sustained

Table 1. DoE independent and dependent variables

Table 2. Runs suggested by the DoE software

release gastroretentive floating tablets using fused filament
fabrication (FFF) 3D printing and evaluate the effect of
formulation and process variables on in vitro drug release
characteristics using Quality by Design (QbD) approach.

METHODS
Hot Melt Extrusion: Hydroxypropyl methylcellulose (HPMC
E5), ethyl cellulose (EC-N14), and acetaminophen (APAP)
(model

drug)

were

blended

using

maxiblend™

(globepharma, new brunswick, NJ, USA) at 25 rpm for 15

Figure 2. In vitro drug release profile of sustained release floating
tablets in 0.1N HCl

Figure 1. Stiffness values of all the extruded filaments
analyzed by Repka-zhang test

minutes. A 11mm twin screw extruder (thermo fisher
scientiﬁc, waltham, MA, USA) was used to extrude

Table 3. Cumulative drug release values of all the
formulations at 2h, 6h and 10thh

Table 4. Model summaries of the QbD experiments

cylindrical filaments with a 1.75mm diameter to be used as

CONCLUSIONS
✓ Filaments

feedstock material for 3D printing.

suitable

for

FFF

3D

printing

were

3D Printing: The tablets were designed as hollow cylindrical

successfully fabricated using different ratios HPMC,

objects (d=12.4mm, h=5mm) to decrease density and float

EC and APAP.
✓ All

in gastric medium, using tinkercad™ free online software
(autodesk, CA, USA). Combining both these digital files and

the

three

process

i3 3D desktop printer, prusa research, prague, czech

characteristics.

republic). The formulation variables (% drug load, EC

6h and 10h were chosen as dependent variables (Table 1,
2 & 3.). A response surface method with three-factor, threelevel box–behnken design was applied for the optimization
of sustained release floating tablets.
Characterization: Thermal stability of polymers in the study
was assessed using thermogravimetric analysis (TGA) and
differential

scanning

calorimetry

(DSC).

Mechanical

properties of the extruded filaments were determined using
a texture analyzer (TA-XT2i analyzer, texture technologies,
MA, USA). (Figure 1.). The printed tablets were evaluated

for in vitro drug release and floating ability in 0.1N HCl
dissolution media. (Figure 2.).

studied

had

✓ QbD was applied to assess the effect of formulation and

tablets were prepared using a FFF based 3D printer (prusa

chosen as independent variables and % drug release at 2h,

factors

significant effect on drug release profiles.

previously extruded filaments, the gastroretentive floating

concentration) and process variables (shell thickness) were

independent

parameters

on

in

vitro

drug

release

✓ Sustained release gastroretentive floating tablets were

✓ The coefficients of % APAP are positive implying that drug dissolution increases with increase in
API load.
✓ Whereas the coefficients of both shell thickness and % EC are negative indicating drug
dissolution decreases with increase in shell thickness or % EC.
✓ % EC had greatest effect on drug release profiles whereas shell thickness had the least effect.
✓ Both % APAP and % EC significantly influenced the drug release at 2h, 6h and 10h (p<0.05),
where as shell thickness had significant effect at only at 2h and 6h and lost effect at 10 h
(p=0.0636).(Table 4.)
✓ No interaction is seen between all three factors (p>0.05), but at 10th h, when shell thickness lost
effect, there is an interaction between drug load and % EC (p=0.0053). (Table 4.).
✓ APAP, is freely water-soluble drug, so as the % APAP increased in formulation , the drug release
increased.
✓ EC is a hydrophobic and water insoluble polymer, so as % EC is increased, drug release
decreased
✓ Shell has separate fill pattern and denser structure compared to core of tablet. So higher shell
thickness successfully prevented the entry of dissolution media for longer time and resulted in
reduced drug release.

prepared with HME coupled 3D printing.
✓ All the printed tablets exhibited good floating behavior
throughout the dissolution studies.
✓ FFF 3D printing combined with QbD is a novel viable tool
for fabricating customized dosage forms for personalized
pharmacotherapy.
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